

Phone: 0522-4062223, 9305548277, 8400888844 9415577933, 9336154100, Tollfree No.: 8688360360

E-mail: charak1984@gmail.com

CMO Reg. No. RMEE 2445133 NABLReg. No. MC-2491 Certificate No. MIS-2023-0218

Patient Name : Ms.NISHA KHAN Visit No : CHA250038024

Age/Gender : 33 Y/F Registration ON : 03/Mar/2025 10:58AM Lab No : 10135319 Sample Collected ON : 03/Mar/2025 11:00AM Referred By : Dr.U1 Sample Received ON : 03/Mar/2025 11:00AM Refer Lab/Hosp : CHARAK NA Report Generated ON 03/Mar/2025 02:19PM

ECG,CHEST PA,TSH,HIV,HCV,HBSAg,PT/PC/INR,LFT,CREATININE,UREA,RANDOM,PLAT COUNT,BTCT,DLC,TLC,HB,BLOOD GROUP Doctor Advice

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

BLOOD GROUP

P.R.

Blood Group "O" **POSITIVE** Rh (Anti -D)

PT/PC/INR			
PROTHROMBIN TIME	13 Second	13 Second	Clotting Assay
Protrhromin concentration	100 %	100 %	
INR (International Normalized Ratio)	1.00	1.0	







Phone: 0522-4062223, 9305548277, 8400888844 9415577933, 9336154100, Tollfree No.: 8688360360

E-mail: charak1984@gmail.com

CMO Reg. No. RMEE 2445133 NABL Reg. No. MC-2491 Certificate No. MIS-2023-0218

Patient Name : Ms.NISHA KHAN Visit No : CHA250038024

Age/Gender : 33 Y/F Registration ON : 03/Mar/2025 10:58AM : 10135319 Lab No Sample Collected ON : 03/Mar/2025 11:00AM Referred By Sample Received ON : Dr.U1 : 03/Mar/2025 11:00AM Refer Lab/Hosp : CHARAK NA Report Generated ON : 03/Mar/2025 02:19PM Doctor Advice : ECG,CHEST PA,TSH,HIV,HCV,HBSAg,PT/PC/INR,LFT,CREATININE,UREA,RANDOM,PLAT COUNT,BTCT,DLC,TLC,HB,BLOOD GROUP

Test Name	Result	Unit	Bio. Ref. Range	Method
HEPATITIS B SURFACE ANTIGEN (HBsAg)				
Sample Type : SERUM				

HEPATITIS B SURFACE ANTIGEN NON REACTIVE <1 - Non Reactive **CMIA** >1 - Reactive

Note: This is only a Screening test. Confirmation of the result (Non Reactive/Reactive) should be done by performing a PCR based test.

COMMENTS:

-HBsAg is the first serological marker after infection with Hepatitis B Virus appearing one to ten weeks after exposure and two to eight weeks before the onset of clinical symptoms. HBsAg persists during the acute phase and clears late in the convalescence phase. Failure to clear HBsAg within six months indicates a chronic HBsAg carrier state. HBsAg assays are used to identify the persons infected with HBV and to prevent transmission of the virus by blood and blood products as well as to monitor the status of infected individuals in combination with other hepatitis B serological markers

-Borderline cases must be confirmed with confirmatory neutralizing assay

LIMITATIONS:

- -Results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute and chronic infections
- -Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA) which may produce anomalous values when tested with assay kits that employs mouse monoclonal
- -Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous results may be observed.

 -Cross reactivity for specimens from individual with medical conditions (Pregnancy, HIV etc) has been observed.

 -HBsAg mutations may result in a false negative result in some HBsAg assays.

- -If HBsAg results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.



DR. NISHANT SHARMA DR. SHADAB **PATHOLOGIST PATHOLOGIST**



: CHA250038024

: 03/Mar/2025 10:58AM

Phone: 0522-4062223, 9305548277, 8400888844 9415577933, 9336154100, Tollfree No.: 8688360360

E-mail: charak1984@gmail.com

CMO Reg. No. RMEE 2445133 NABL Reg. No. MC-2491 Certificate No. MIS-2023-0218

Visit No

Registration ON

Patient Name : Ms. NISHA KHAN

Age/Gender : 33 Y/F **Lab No** : 10135319

Referred By : Dr.U1
Refer Lab/Hosp : CHARAK NA

: Dr.U1 : CHARAK NA Sample Collected ON : 03/Mar/2025 11:00AM

Sample Received ON : 03/Mar/2025 11:00AM

: CHARAK NA Report Generated ON : 03/Mar/2025 02: 19PM : ECG,CHEST PA,TSH,HIV,HCV,HBSAg,PT/PC/INR,LFT,CREATININE,UREA,RANDOM,PLAT COUNT,BTCT,DLC,TLC,HB,BLOOD GROUP

				<u> </u>
Test Name	Result	Unit	Bio. Ref. Range	Method
HIV				

HIV-SEROLOGY

Doctor Advice

NON REACTIVE

<1.0 : NON REACTIVE >1.0 : REACTIVE

Done by: Vitros ECI (Sandwich Assay)

Note:-Elisa test is a screening method for HIV.It is known to give false Positive & Negative result.

Hence confirmation: "Western Blot" method is advised.

HCV

Anti-Hepatitis C Virus Antibodies.

NON REACTIVE

< 1.0 : NON REACTIVE

Sandwich Assay

> 1.0 : REACTIVE

Done by: Vitros ECI (Sandwich Assay)

Note: This is only a Screening test. Confirmation of the result (Non Reactive/Reactive) should be done by performing a PCR based test.

BT/CT

BLEEDING TIME (BT) CLOTTING TIME (CT) 3 mint 15 sec

mins

2 - 8

6 mint 30 sec

3 - 10 MINS.





Olgrand.



Phone: 0522-4062223, 9305548277, 8400888844 9415577933, 9336154100, Tollfree No.: 8688360360

E-mail: charak1984@gmail.com

CMO Reg. No. RMEE 2445133 NABL Reg. No. MC-2491 Certificate No. MIS-2023-0218

Patient Name : Ms. NISHA KHAN Visit No : CHA250038024

Age/Gender : 33 Y/F Registration ON : 03/Mar/2025 10:58AM Lab No : 10135319 Sample Collected ON : 03/Mar/2025 11:00AM Referred By : Dr.U1 Sample Received ON : 03/Mar/2025 11:30AM Refer Lab/Hosp : CHARAK NA Report Generated ON : 03/Mar/2025 12:35PM

Doctor Advice : ECG,CHEST PA,TSH,HIV,HCV,HBSAg,PT/PC/INR,LFT,CREATININE,UREA,RANDOM,PLAT COUNT,BTCT,DLC,TLC,HB,BLOOD GROUP

Test Name	Result	Unit	Bio. Ref. Range	Method
HAEMOGLOBIN				
Hb	13.2	g/dl	12 - 15	Non Cyanide

Comment:

P.R.

Hemoglobin screening helps to diagnose conditions that affect RBCs such as anemia or polycythemia.

TLC				
TOTAL LEUCOCYTES COUNT	9090	/cmm	4000 - 10000	Flocytrometry
DLC				
NEUTROPHIL	52	%	40 - 75	Flowcytrometry
LYMPHOCYTE	36	%	20-40	Flowcytrometry
EOSINOPHIL	9	%	1 - 6	Flowcytrometry
MONOCYTE	3	%	2 - 10	Flowcytrometry
BASOPHIL	0	%	00 - 01	Flowcytrometry
PLATELET COUNT				
PLATELET COUNT	268,000	/cmm	150000 - 450000	Elect Imped
PLATELET COUNT (MANUAL)	268000	/cmm	150000 - 450000	Microscopy.
BLOOD SUGAR RANDOM				
BLOOD SUGAR RANDOM	100	mg/dl	70 - 170	Hexokinase
BLOOD UREA				
BLOOD UREA	21.00	mg/dl	15 - 45	Urease, UV, Serum
SERUM CREATININE				
CREATININE	0.60	mg/dl	0.50 - 1.40	Alkaline picrate- kinetic
LIVER FUNCTION TEST				
TOTAL BILIRUBIN	0.64	mg/dl	0.4 - 1.1	Diazonium Ion
CONJUGATED (D. Bilirubin)	0.12	mg/dL	0.00-0.30	Diazotization
UNCONJUGATED (I.D. Bilirubin)	0.52	mg/dL	0.1 - 1.0	Calculated
ALK PHOS	111.90	U/L	30 - 120	PNPP, AMP Buffer
SGPT	51.0	U/L	5 - 40	UV without P5P
SGOT	33.0	U/L	5 - 40	UV without P5P





Phany



Phone: 0522-4062223, 9305548277, 8400888844 9415577933, 9336154100, Tollfree No.: 8688360360

E-mail: charak1984@gmail.com

CMO Reg. No. RMEE 2445133 NABL Reg. No. MC-2491 Certificate No. MIS-2023-0218

Patient Name : Ms. NISHA KHAN Visit No : CHA250038024

Age/Gender : 33 Y/F Registration ON : 03/Mar/2025 10:58AM Lab No : 10135319 Sample Collected ON : 03/Mar/2025 11:00AM Referred By : Dr.U1 Sample Received ON : 03/Mar/2025 11:30AM Refer Lab/Hosp : CHARAK NA Report Generated ON 03/Mar/2025 12:35PM

Doctor Advice : ECG,CHEST PA,TSH,HIV,HCV,HBSAg,PT/PC/INR,LFT,CREATININE,UREA,RANDOM,PLAT COUNT,BTCT,DLC,TLC,HB,BLOOD GROUP



Test Name	Result	Unit	Bio. Ref. Range	Method
TSH				
TSH	2.77	uIU/ml	0.47 - 4.52	ECLIA

Note

- (1) Patients having low T3 & T4 levels but high TSH levels suffer from primary hypothyroidism, cretinism, juvenile mysedema or autoimmune disorders.
- (2) Patients having low T3 & T4 levels but high TSH levels suffer from grave~s disease, toxic adenoma or sub-acute thyroiditis.
- (3) Patients having either low or normal T3 & T4 levels but low TSH values suffer from iodine deficiency or secondary hypothyroidism.
- (4) Patients having high T3 & T4 levels but normal TSH levels may suffer from toxic multinodular goitre. This condition is mostly asymptomatic and may cause transient hyperthyroidism but no persistent symptoms.
- (5) Patient with high or normal T3 & T4 levels and low or normal TSH levels suffer either from T3 toxicosis or T4 Toxicosis respectively.
- (6) In patients with non thyroidal illness abnormal test results are not necessarily indicative of thyroidism but may be due to adaptation to the cacabolic state and may revert tonormal when the patient recovers.
- (7) There are many drugs for eg.Glucocorticoids ,dopamine,Lithium,iodides ,oral radiographic dyes,ets.Which may affect the thyroid function tests.
- (8) Generally when total T3& T4 results are indecisive then Free T3 & Free T4 test are recommended for further confirmation along with

(1 Beckman DxI-600 2. ELECTRO-CHEMILUMINISCENCE TECHINIQUE BY ELECSYSYS -E411)

*** End Of Report ***

CHARAK





Than

Patient Name

: Ms.NISHA KHAN

Age/Gender

: 33 Y/F

Lab No

PR.

: 10135319

Referred By

: Dr.U1

Refer Lab/Hosp

: CHARAK NA

Visit No : CHA250038024

Registration ON : 03/Mar/2025 10:58AM

Sample Collected ON

: 03/Mar/2025 10:58AM

Sample Received ON

Report Generated ON : 03/Mar/2025 11:58AM

ECG-REPORT

RATE : 80 bpm

* RHYTHM : Normal

* P wave : Normal

* PR interval : Normal

* QRS Axis : Normal

Duration : Normal

Configuration : Normal

* ST-T Changes : None

* QT interval :

* QTc interval : Sec.

* Other :

OPINION: ECG WITH IN NORMAL LIMITS

(FINDING TO BE CORRELATED CLINICALLY)

[DR. PANKAJ RASTOGI, MD, DM]



Patient Name : Ms.NISHA KHAN Visit No : CHA250038024

 Age/Gender
 : 33 Y/F
 Registration ON
 : 03/Mar/2025 10:58AM

 Lab No
 : 10135319
 Sample Collected ON
 : 03/Mar/2025 10:58AM

Referred By : Dr.U1 Sample Received ON

Refer Lab/Hosp : CHARAK NA Report Generated ON : 03/Mar/2025 12:56PM

SKIAGRAM CHEST PA VIEW

- Both lung fields are clear.
- Bilateral hilar shadows are normal.
- Cardiac shadow is within normal limits.
- Both CP angles are clear.
- Soft tissue and bony cage are seen normally.
- Both domes of diaphragm are sharply defined.

IMPRESSION:

• NO ACTIVE LUNG PARENCHYMAL LESION IS DISCERNIBLE.

Clinical correlation is necessary.

[DR. RAJESH KUMAR SHARMA, MD]

transcribed by: anup

*** End Of Report ***

